Hypertriglyceridemia in Reference to Chronic Kidney Disease

Abstract

Introduction: Chronic kidney disease is in increasing trend due to increase inprevalence of Diabetes mellitus and Hypertension. Dyslipidemia is most common entity seen in chronic kidney disease patients and is responsible for Cardiovascular Disease (coronary artery disease). Hypertriglyceridemia is most common form of deranged lipid profile seen in them. So its utmost importance to identify dyslipidemia and treatment of the same to prevent morbidity and mortality related to it. Methods: It is a case control study conducted in NSCB MCH JBP, MP after ethical committee clearance. Where, Subjects of 50 in number who are healthy people placed in Group-1, CKD patients who never underwent hemodialysis of 50 in number are in Group-2 and CKD patients who are on maintenance hemodialysis of 50 in number in Group-3. The baseline characteristics were noted and baseline investigations are done and after 12 hours of fasting, blood is collected for lipid profile, the values are tabulated and compared with each group. Results: In our study we found that, there is increase in Tryglycerides (TG) in CKD patients with and without hemodialysis. The values are more consistent with increase in stages of CKD. TG values are more high in group 3 compared to group 2. Also TG values are higher in CKD patients with Diabetes Mellitus compared to CKD patients without DM. The values were statistically significant in each comparison (pvalue <0.05). Along with Triglycerides (TG), Very Low Density Lipoprotein (VLDL), Low Density Lipoprotein (LDL) and Total Cholesterol increased in group 2 and 3 compare to group 1. High Density Lipoprotein (HDL) is decreased in group 2 and 3 compare to healthy patients. Conclusion: Present study demonstrated that there is dyslipidemia with predominant hypertriglyceridemia in CKD patients irrespective of mode of management, but the derangement is much more common and significant in CKD with hemodialysis group and they are at high risk of cardiovascular disease. So one should consider to start lipid lowering drugs which decreases disease progression and dyslipidemia and its related morbidity and mortality.